Stocks and Investing
Stocks and Investing
Wed, December 20, 2017
[ Wed, Dec 20th 2017
] - WOPRAI
Tue, December 19, 2017
[ Tue, Dec 19th 2017
] - WOPRAI
[ Tue, Dec 19th 2017
] - WOPRAI
[ Tue, Dec 19th 2017
] - WOPRAI
[ Tue, Dec 19th 2017
] - WOPRAI
Mon, December 18, 2017
[ Mon, Dec 18th 2017
] - WOPRAI
[ Mon, Dec 18th 2017
] - WOPRAI
[ Mon, Dec 18th 2017
] - WOPRAI
[ Mon, Dec 18th 2017
] - WOPRAI
[ Mon, Dec 18th 2017
] - WOPRAI
[ Mon, Dec 18th 2017
] - WOPRAI
Christopher Raymond Initiated (AKBA) at Buy and Held Target at $26 on, Dec 18th, 2017
Christopher Raymond of Piper Sandler, Initiated "Akebia Therapeutics, Inc." (AKBA) at Buy and Held Target at $26 on, Dec 18th, 2017.
Christopher has made no other calls on AKBA in the last 4 months.
There are 2 other peers that have a rating on AKBA. Out of the 2 peers that are also analyzing AKBA, 0 agree with Christopher's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Christopher
- Robert Hazlett of "BTIG" Initiated at Strong Buy and Held Target at $30 on, Thursday, December 7th, 2017
- Difei Yang of "Mizuho" Initiated at Strong Buy and Held Target at $24 on, Thursday, October 5th, 2017
Contributing Sources
Similar Stocks and Investing Articles
[ Thu, Dec 07th 2017
] - WOPRAI
[ Thu, Nov 09th 2017
] - WOPRAI
[ Mon, Nov 06th 2017
] - WOPRAI
[ Fri, Oct 27th 2017
] - WOPRAI
[ Wed, Oct 25th 2017
] - WOPRAI
[ Tue, Oct 24th 2017
] - WOPRAI
[ Mon, Oct 23rd 2017
] - WOPRAI
[ Fri, Dec 18th 2015
] - WOPRAI
[ Fri, Dec 18th 2015
] - WOPRAI